SQNM Likely To Develop High Margin Diagnostic Products
Symbols: SQNM
Tags: Cantor Fitzgerald
Analysts at Cantor Fitzgerald maintain their "buy" rating on Sequenom (NASDAQ: SQNM). The target price for SQNM has been reduced from $16 to $13.
According to Cantor Fitzgerald, the target has been lowered to reflect anticipated dilution and settlement of a class action suit. Cantor Fitzgerald believes, however, that SQNM can develop high margin diagnostic products.
SQNM’s shares lost 4.28% to $5.82 at 2:45 pm. More Analyst Ratings here
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
